Cargando…

Comparison of Standard 1.5 T vs. 3 T Optimized Protocols in Patients Treated with Glatiramer Acetate. A Serial MRI Pilot Study

This study explored the effect of glatiramer acetate (GA, 20 mg) on lesion activity using the 1.5 T standard MRI protocol (single dose gadolinium [Gd] and 5-min delay) or optimized 3 T protocol (triple dose of Gd, 20-min delay and application of an off-resonance saturated magnetization transfer puls...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zivadinov, Robert, Hojnacki, David, Hussein, Sara, Bergsland, Niels, Carl, Ellen, Durfee, Jacqueline, Dwyer, Michael G., Kennedy, Cheryl, Weinstock-Guttman, Bianca
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Molecular Diversity Preservation International (MDPI) 2012
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3382749/ https://www.ncbi.nlm.nih.gov/pubmed/22754322 http://dx.doi.org/10.3390/ijms13055659

Ejemplares similares

Effect of Treatment with Interferon Beta-1a on Changes in Voxel-Wise Magnetization Transfer Ratio in Normal Appearing Brain Tissue and Lesions of Patients with Relapsing–Remitting Multiple Sclerosis: A 24-Week, Controlled Pilot Study
por: Zivadinov, Robert, et al.
Publicado: (2014)

Immunologic and MRI markers of the therapeutic effect of IFN-β-1a in relapsing-remitting MS
por: Tao, Yazhong, et al.
Publicado: (2015)

Immunological and short-term brain volume changes in relapsing forms of multiple sclerosis treated with interferon beta-1a subcutaneously three times weekly: an open-label two-arm trial
por: Dwyer, Michael G., et al.
Publicado: (2015)

Effect of Teriflunomide and Dimethyl Fumarate on Cortical Atrophy and Leptomeningeal Inflammation in Multiple Sclerosis: A Retrospective, Observational, Case-Control Pilot Study
por: Zivadinov, Robert, et al.
Publicado: (2019)

Decreased brain venous vasculature visibility on susceptibility-weighted imaging venography in patients with multiple sclerosis is related to chronic cerebrospinal venous insufficiency
por: Zivadinov, Robert, et al.
Publicado: (2011)

Hypoperfusion of brain parenchyma is associated with the severity of chronic cerebrospinal venous insufficiency in patients with multiple sclerosis: a cross-sectional preliminary report
por: Zamboni, Paolo, et al.
Publicado: (2011)

Serum lipid profiles are associated with disability and MRI outcomes in multiple sclerosis
por: Weinstock-Guttman, Bianca, et al.
Publicado: (2011)

Clinical feasibility of longitudinal lateral ventricular volume measurements on T2-FLAIR across MRI scanner changes
por: Jakimovski, Dejan, et al.
Publicado: (2021)

Retinal Blood Vessel Analysis Using Optical Coherence Tomography (OCT) in Multiple Sclerosis
por: Young, Nicholas, et al.
Publicado: (2023)

Longitudinal analysis of cerebral aqueduct flow measures: multiple sclerosis flow changes driven by brain atrophy
por: Jakimovski, Dejan, et al.
Publicado: (2020)

Neuroimaging Correlates of Patient-Reported Outcomes in Multiple Sclerosis
por: Jakimovski, Dejan, et al.
Publicado: (2023)

Decreasing brain iron in multiple sclerosis: The difference between concentration and content in iron MRI
por: Schweser, Ferdinand, et al.
Publicado: (2020)

Serum Neurofilament Light Chain Levels are Associated with Lower Thalamic Perfusion in Multiple Sclerosis
por: Jakimovski, Dejan, et al.
Publicado: (2020)

Follow-on glatiramer acetate
por: Cohen, Jeffrey A., et al.
Publicado: (2018)

Iron-related gene variants and brain iron in multiple sclerosis and healthy individuals
por: Hagemeier, Jesper, et al.
Publicado: (2017)

Chronic cerebrospinal venous insufficiency is not associated with cognitive impairment in multiple sclerosis
por: Benedict, Ralph HB, et al.
Publicado: (2013)

The Effect of Three Times a Week Glatiramer Acetate on Cerebral T1 Hypointense Lesions in Relapsing‐Remitting Multiple Sclerosis
por: Zivadinov, Robert, et al.
Publicado: (2015)

Efficacy and Safety of 2 Fingolimod Doses vs Glatiramer Acetate for the Treatment of Patients With Relapsing-Remitting Multiple Sclerosis: A Randomized Clinical Trial
por: Cree, Bruce A. C., et al.
Publicado: (2021)

Reserve-related activities and MRI metrics in multiple sclerosis patients and healthy controls: an observational study
por: Schwartz, Carolyn E., et al.
Publicado: (2016)

An Observational Study to Assess Brain MRI Change and Disease Progression in Multiple Sclerosis Clinical Practice—The MS‐MRIUS Study
por: Zivadinov, Robert, et al.
Publicado: (2016)

MRI segmentation analysis in temporal lobe and idiopathic generalized epilepsy
por: Goldberg, Hila, et al.
Publicado: (2014)

Quantifying disease pathology and predicting disease progression in multiple sclerosis with only clinical routine T2-FLAIR MRI
por: Fuchs, Tom A., et al.
Publicado: (2021)

Proteomics and relationship with axonal pathology in multiple sclerosis: 5-year diffusion tensor imaging study
por: Jakimovski, Dejan, et al.
Publicado: (2023)

Glatiramer acetate in the treatment of multiple sclerosis
por: Tselis, Alex, et al.
Publicado: (2007)

Risk Factors for Chronic Cerebrospinal Venous Insufficiency (CCSVI) in a Large Cohort of Volunteers
por: Dolic, Kresimir, et al.
Publicado: (2011)

Changes of deep gray matter magnetic susceptibility over 2 years in multiple sclerosis and healthy control brain
por: Hagemeier, Jesper, et al.
Publicado: (2017)

Multimodal noninvasive and invasive imaging of extracranial venous abnormalities indicative of CCSVI: Results of the PREMiSe pilot study
por: Zivadinov, Robert, et al.
Publicado: (2013)

Demonstration of Equivalence of Generic Glatiramer Acetate and Copaxone(®)
por: Lipsky, Peter, et al.
Publicado: (2021)

Clinical correlates of chronic cerebrospinal venous insufficiency in multiple sclerosis
por: Weinstock-Guttman, Bianca, et al.
Publicado: (2012)

Long-term efficacy and safety of three times weekly dosing regimen of glatiramer acetate in relapsing multiple sclerosis patients: Seven-year results of the Glatiramer Acetate Low-frequency Administration (GALA) open-label extension study
por: Rieckmann, Peter, et al.
Publicado: (2021)

Cortical and Deep Gray Matter Perfusion Associations With Physical and Cognitive Performance in Multiple Sclerosis Patients
por: Jakimovski, Dejan, et al.
Publicado: (2020)

Switching from branded to generic glatiramer acetate: 15-month GATE trial extension results
por: Selmaj, Krzysztof, et al.
Publicado: (2017)

Neurological software tool for reliable atrophy measurement (NeuroSTREAM) of the lateral ventricles on clinical-quality T2-FLAIR MRI scans in multiple sclerosis
por: Dwyer, Michael G., et al.
Publicado: (2017)

The role of glatiramer acetate in the early treatment of multiple sclerosis
por: Brandes, David W
Publicado: (2010)

Spasticity in multiple sclerosis and role of glatiramer acetate treatment
por: Meca-Lallana, Jose Eustasio, et al.
Publicado: (2015)

Glatiramer Acetate-associated Refractory Immune Thrombocytopenic Purpura
por: Sagy, Iftach, et al.
Publicado: (2016)

Physicochemical and Biological Examination of Two Glatiramer Acetate Products
por: Komlosh, Arthur, et al.
Publicado: (2019)

Bullous pemphigoid as an injection site reaction of glatiramer acetate
por: Baghbanian, Seyed Mohammad, et al.
Publicado: (2019)

Glatiramer Acetate Immunomodulation: Evidence of Neuroprotection and Cognitive Preservation
por: Kasindi, Arielle, et al.
Publicado: (2022)

An Immunomodulatory Peptide Dendrimer Inspired from Glatiramer Acetate
por: Erzina, Dina, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_2b93f8hdsfu56qq5du2qnd11ct